The importance of clinical pharmacokinetic–pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes by McCallum, Andrew D & Sloan, Derek James
195Int. J. Pharmacokinet. (2017) 2(3), 195–212 ISSN 2053-084610.4155/ipk-2017-0004 © 2017 Andrew D McCallum
part of
Review
Int. J. Pharmacokinet.
Review
2
3
2017
Tuberculosis remains a major infectious cause of morbidity and mortality worldwide. 
Current antibiotic regimens, constructed prior to the development of modern 
pharmacokinetic-pharmacodynamic (PK–PD) tools, are based on incomplete 
understanding of exposure–response relationships in drug susceptible and multidrug 
resistant tuberculosis. Preclinical and population PK data suggest that clinical PK–PD 
studies may enable therapeutic drug monitoring for some agents and revised dosing 
for others. Future clinical PK–PD challenges include: incorporation of PK methods 
to assay free concentrations for all active metabolites; selection of appropriate 
early outcome measures which reflect therapeutic response; elucidation of genetic 
contributors to interindividual PK variability; conduct of targeted studies on special 
populations (including children); and measurement of PK–PD parameters at the site 
of disease.
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In 2015 there were an estimated 10.4 mil-
lion new tuberculosis (TB) cases, 1.4 million 
TB deaths in HIV uninfected patients and 
0.4 million TB deaths among people living 
with HIV [1]. Despite significant progress 
since the 1990s, the WHO End TB Strategy 
aim of ‘a world free of TB’ by 2035 will not 
be achieved without scientific advances to 
improve antituberculous chemotherapy. To 
evaluate the role of clinical pharmacokinetic 
(PK) and pharmacodynamic (PD) stud-
ies in reaching this target it is necessary to 
understand the problems with current treat-
ment and review desirable attributes for new 
 antibiotic regimens.
Current problems & priority goals 
for TB therapeutics
Between 1946 and 1986, a series of mul-
ticenter clinical trials conducted by the 
B ritish Medical Research Council and oth-
ers demonstrated that patients suffering from 
drug-susceptible (DS)-TB, caused by Myco-
bacterium tuberculosis (Mtb) bacteria in the 
absence of antimicrobial resistance, could 
be cured by a 6-month course of combina-
tion therapy (2 months of rifampicin, isonia-
zid, pyrazinamide and ethambutol followed 
by 4 months of rifampicin and isoniazid) 
with a 5–8% post-treatment relapse rate at 
2 years [2]. These data informed the design 
of current ‘short-course’ treatment regimens 
and TB seemed destined to become a disease 
of the past.
However, the late 20th century saw a dra-
matic TB resurgence with the major burden 
of illness in low and middle income coun-
tries. Particularly in sub-Saharan Africa, the 
co-existent HIV pandemic catalyzed a sharp 
rise in TB incidence, making adherence of 
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every patient to 6 months of chemotherapy impossible 
for public health services to support [3]. To exacerbate 
matters, antituberculous drugs can cause significant 
toxicity and some components (principally rifampicin) 
are associated with problematic drug–drug interac-
tions when combined with antiretroviral therapy [4]. 
Poor adherence and complex polypharmacy leads to 
unfavorable outcomes and it has become apparent that 
shorter TB treatment is needed [5]. Mathematical mod-
eling suggests that shortening effective chemotherapy 
to 2 months could reduce TB incidence by 20%, 
and mortality by 25%. More modest gains could be 
achieved by treatment abbreviation to 4 months [6].
Linked to failures in DS-TB therapy, a marked 
increase has been observed in the incidence of mul-
tidrug resistant (MDR-) TB, caused by Mtb bacteria 
which are resistant to both rifampicin and isoniazid. 
The estimated number of MDR-TB cases worldwide 
rose from 250,000 in 2009 to 480,000 in 2015 [1]. 
Extensively drug-resistant TB, with super-added resis-
tance to injectable second line drugs and fluoroquino-
lones, comprises 10% of MDR-TB cases. Some of the 
highest rates are in Eastern Europe where the collapse 
of health infrastructure during the disintegration of 
the Soviet Union contributed to difficulties for DS-TB 
treatment completion [7].
MDR-TB typically requires treatment prolongation 
to 18–20 months, although the WHO has approved 
the use of a 9- to 12-month regimen in some circum-
stances [8]. The second line drugs used for MDR-TB 
carry additional toxicities so the need for faster, cleaner 
therapy is even stronger than in drug susceptible 
d isease [9,10].
The question for clinical pharmacologists is whether 
detailed interrogation of antibiotic exposure–response 
relationships will accelerate development of shorter, 
less toxic therapy for all forms of TB.
A role for clinical PK–PD studies in achieving 
these goals
The clinical trial sequence that resulted in current 
short course chemotherapy for DS-TB was completed 
by 1985, and moved directly from Phase I studies of 
restricted scope to pivotal Phase III trials [2]. Modern 
PK–PD tools and population pharmacokinetic analy-
sis had not yet been established [5]. Consequently, cor-
relation between drug concentration and therapeutic 
effect was incompletely evaluated.
Subsequent preclinical experiments have derived 
summary PK measures, including the maximum drug 
concentration (C
max
) or area under the concentration-
time curve (AUC), from murine [11,12] or hollow fibre 
system (HFS) models [13–18] of TB disease. These 
parameters may be expressed relative to the minimum 
inhibitory concentration (MIC) of each antibiotic for 
the infecting Mtb isolate, and related to the rate of bac-
terial clearance from the model. Results suggest that 
the efficacy of rifampicin, isoniazid, pyrazinamide and 
ethambutol is driven by AUC/MIC [13,15–17]. For rifam-
picin, isoniazid and ethambutol there is also a relation-
ship between efficacy and C
Max
/MIC [15–17]. Data from 
retrospective meta-analyses contend that the PK–PD 
indices associated with efficacy in HFS studies are also 
relevant to clinical disease [18].
Alongside this thought-provoking preclinical PK–
PD work sits a growing body of population PK litera-
ture revealing up to tenfold interindividual variability 
in plasma PK indices for first-line antituberculous 
drugs [19–22]. Studies comparing drug concentrations 
(particularly the C
Max
 of rifampicin) to a predefined 
reference range invariably showed antibiotic exposure 
to be unpredictable and lower than expected [23,24], 
giving rise to the argument that more detailed clinical 
PK–PD studies are needed to delineate the contribu-
tion of inadequate antibiotic exposure to unfavorable 
outcomes. Two potential benefits are cited for this 
approach; improved knowledge of the PK–PD drivers 
of treatment success may enable early phase clinical 
trials to predict whether dose escalation of key agents 
could facilitate treatment shortening in new standard-
ized regimens, and greater understanding of early 
PK–PD targets linked to long-term cure may permit 
therapeutic drug monitoring (TDM) and intensifica-
tion of therapy for patients at high risk of unfavorable 
outcomes.
Clinical PK–PD study design
A generic design to provide an overview of clinical PK–
PD studies in TB is outlined in Figure 1. For illustra-
tion, only the current 6-month treatment regimen for 
DS-TB is shown but timescales and regimens may be 
adapted for MDR-TB. PK–PD studies nested within 
early phase clinical trials may compare multiple drugs 
and dose combinations.
Blood sampling for plasma or serum PK assays is 
generally drawn after daily medications have reached a 
steady state concentration cycle, typically after at least 
14 days of therapy. Intensive PK sampling to establish 
the AUC for the 24 h after dosing (AUC
0–24
) is costly 
and labor intensive because a minimum of six or seven 
blood samples must be collected at carefully recorded 
time-points. All specimens should be promptly centri-
fuged so that plasma or serum can be harvested and 
frozen at 80°C, prior to batched analysis by HPLC 
and mass spectrometry. For studies in TB endemic, 
resource poor countries bioanalysis often requires cold 
shipment to distant laboratories. Novel approaches to 
measuring drug exposure or activity in resource-limited 
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Figure 1.  Generic study design for clinical PK–PD study in DS-TB. Procedures to generate PK parameters are 
shown in green. Procedures to generate PD parameters and study outcome measures are shown in red. PK–PD 
parameters which may be related to study outcome measures are shown in yellow.  
Number before drug combinations denotes intended duration of therapy in months. Other abbreviations are as 
described in the main text.  
*TB cultures to determine early efficacy measures may be set up in solid or liquid culture.  
‡Treatment failure is normally defined as persistently positive sputum cultures until the end of TB therapy.  
§Relapse is normally defined as cure (negative sputum culture) at the end of TB therapy but reversion to positive 
cultures with the same Mtb strain as the baseline isolate during post-treatment follow-up. 
E: Ethambutol; H: Isoniazid; MIC: Minimum inhibitory concentration; Mtb: Mycobacterium tuberculosis;  
PTB: Pulmonary tuberculosis; R: Rifampicin; SCC: Sputum culture conversion; Z: Pyrazinamide.
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settings include the use of dried blood spot methods to 
store and transport samples [25–27], urine colorimetry 
to detect low rifampicin exposure [28] or co-culturing 
patients’ Mtb isolate with their plasma on treatment 
in liquid culture to give an indication of the relative 
activity of the treatment regimen [29]. For some anti-
tuberculous drugs (e.g., amikacin [30], kanamycin [30], 
moxifloxacin [31] and linezolid [32] in MDR-TB) lim-
ited plasma sampling strategies have sought to deter-
mine which single time-point measurements best rep-
resent more complex PK indices. For other antibiotics 
(e.g., rifampicin) Bayesian statistical techniques have 
been deployed to calculate AUCs from sparse sampling 
strategies (often two to three blood draws) [33]. Poten-
tial drawbacks to the Bayesian approach are the need 
for prior intensive PK data from the same population 
and reliance on sophisticated computer software [34]. 
There is also a lack of consensus on optimum sparse 
sampling time-points for some drugs.
As with preclinical studies, it is recognized that 
antibiotic PK parameters such as AUC and C
max
 should 
be related to the MIC of each drug for the infecting 
Mtb isolate. In fact, lack of detailed e pidemiological 
data on MIC distributions for Mtb from most high-
incidence TB settings [35,36] makes calculation of 
AUC/MIC and C
Max
/MIC more important for clini-
cal pharmacology studies than for murine or HFS 
models. Mtb MIC assay plates covering most first 
and second line antituberculous drugs are available 
which may expand access to PK–PD testing for TB 
patients [37], and there have been some practical 
applications of this approach [38,39]. Correlation of 
specific genetic mutations in the Mtb genotype with 
MIC range for some drugs (e.g., gyrA mutations and 
fluoroquinolone MICs) may also provide more rapid, 
detailed information than is currently available on 
the complexity of variable drug susceptibility in the 
clinical setting [40].
Once PK–PD parameters have been established, 
selection of appropriate outcome markers is not 
straightforward. While some studies focus on toxicity 
or induction of antibiotic resistance, a common pur-
pose is to identify relationships with treatment efficacy. 
Strengths and weaknesses of TB efficacy end points 
in regular use by clinical researchers are outlined in 
Table 1.
198 Int. J. Pharmacokinet. (2017) 2(3) future science group
Review    McCallum & Sloan
The risk of TB relapse after completion of therapy 
is well recognized, so definitive Phase III clinical trials 
in DS-TB conventionally use a late efficacy outcome 
of relapse-free cure 18–24 months after enrollment as 
their gold standard end point [2,41]. TDM studies seek-
ing to identify and validate PK–PD targets linked to 
long-term cure would also ideally be validated against 
this late outcome. However, trials of this duration, or 
longer for MDR-TB, are complicated and expensive to 
complete [10]. From this perspective, clinical PK–PD 
analyses based on earlier efficacy outcomes in Phase II 
trials may help to compare novel combinations of 
drugs and dosages using fewer patients over a shorter 
timeframe so that only candidate regimens with the 
greatest efficacy and treatment shortening potential 
advance to Phase III evaluation.
For this approach, the early outcomes of Phase II 
studies should predict relapse. Traditionally, for DS-TB 
patients with pulmonary TB, sputum culture c onversion 
(SCC) from ‘positive’ to ‘negative’ at two months is used 
to represent treatment efficacy [42]. However, this sim-
ple biomarker shows only modest correlation with late 
outcomes [41,42]. In recent years, attention has shifted 
toward weekly sputum sampling to more accurately 
record the ‘time to culture conversion’ and provide more 
information on the antibacterial effect of therapy over 
the entire study period than binary measurement at a 
single time-point [43,44]. Modern studies have also seen 
a gradual move from microbiological treatment moni-
toring on solid (e.g., Lowenstein-Jensen [LJ]) media to 
liquid culture (e.g., the mycobacterial growth indicator 
tube system) because liquid Mtb culture is easier, pro-
vides faster results and converts to ‘negative’ later during 
therapy [45,46]. It is generally believed that TB relapse is 
driven by drug-tolerant bacteria which survive despite 
antibiotic therapy [5]. Therefore, while the PD of distinct 
bacterial phenotypes in different media are incompletely 
understood [47], it seems intuitive that liquid culture 
Table 1. Treatment efficacy outcomes used in clinical pharmacokinetic-pharmacodynamic studies and clinical trials for 
tuberculosis.
Timing of outcome 
measurement
Outcome measurement Strengths Weaknesses
Late 
(typically the end 
of post-treatment 
follow-up)
Treatment failure or 
post-treatment relapse
1. Clinically relevant (target PK–
PD parameters for TDM would 
ideally be validated against this 
outcome) 
2. Gold standard end point for 
stable cure in Phase III clinical 
trials
1. Studies are very long and expensive to 
conduct 
2. Unless careful molecular tests can be 
undertaken the end point of relapse may 
be contaminated by TB re-infection in 
highly endemic settings, especially with 
high rates of HIV co-infection
Early 
(typically 2 months 
for DS-TB, may be  
24 weeks for  
MDR-TB)
SCC† at a defined end 
point
1. Results are simple to 
understand and interpret 
2. Only requires sputum sampling 
at two time-points
1. Only modest correlation with late 
outcomes 
2. Binary data do not use all information 
(e.g., 2-month results cannot 
discriminate between patients who are 
culture negative at 8 weeks, even if one 
culture converted at 2 weeks and the 
other at 6 weeks)
 Time to SCC† 1. Results are simple to 
understand and interpret 
2. Provides more discriminatory 
data than SCC
1. Correlation with late outcomes has not 
been well validated 
2. Weekly sputum sampling required; 
wider sampling windows reduce the 
accuracy of the measurement
 Statistical modeling of 
bacterial elimination 
rates from serial 
quantitative 
bacteriology data‡
1. Provides information on 
antimicrobial efficacy across the 
whole sampling time, even on 
patients who do not convert to 
negative 
2. Allows multiphase patterns of 
bacterial clearance to be assessed
1. Correlation of summary parameters 
from mixed effects modeling with late 
outcomes has not been well validated 
2. Data analysis is computationally 
complex to perform 
3. Results are not always simple to 
understand and interpret
†SCC or ‘time to SCC’ data can be generated using solid or liquid culture media; culture conversion is often later in liquid culture systems.
‡Quantitative bacteriology data can be generated from log
10
CFU/ml counts on solid media to Time to Positive results in liquid culture systems.
DS-TB: Drug-susceptible TB; MDR-TB: Multidrug resistant TB; PK–PD: Pharmacokinetic–pharmacodynamic; SCC: Sputum culture conversion; TDM: Therapeutic drug 
monitoring.
199www.future-science.comfuture science group
Importance of clinical PK–PD studies in unraveling the determinants of early & late TB outcomes   Review
systems which revive ‘persister’ organisms for longer 
will provide better surrogates of final outcomes [48,49]. 
Some reports indicate that liquid culture may still fail to 
revive a proportion of differentially culturable ‘persister’ 
cells, which only grow from expectorated sputum when 
media is augmented with exogenous culture filtrate (CF) 
or resuscitation-promoting factors [50,51]. The effect of 
antibiotic therapy on CF- or resuscitation-promoting 
factors-dependent bacilli may also be important deter-
minants of TB treatment response, but the relationship 
between survival of these cells and clinical outcomes has 
not been evaluated.
Newer methods to monitor TB treatment response 
and set early outcome measures for PK–PD studies 
involve use of serial quantitative bacteriology to chart 
the decline in Mtb bacillary load. In solid media, incu-
bation of homogenized sputum onto on selective agar 
plates (e.g., Middlebrook 7H10 or 7H11) allows the 
number of colony forming units (usually expressed in 
log
10
CFU/ml) in each expectorated patient sample to be 
counted [52–54]. For liquid culture, the time to positiv-
ity after inoculation of processed sputum into Myco-
bacterial Growth Indicator Tubes provides an inverse 
measure of bacillary load (usually expressed in hours 
or days) because shorter delay until detection of growth 
represents higher bacterial burden [53,55–56]. Early bac-
tericidal activity studies lasting up to 14 days directly 
report changes from baseline in log
10
CFU/ml counts or 
time to positivity [48,57], while studies extending out for 
8–12 weeks may deploy statistical modeling techniques 
to summarize evolving patterns of bacillary clearance 
over a longer period [53,58–59]. Separate elimination rates 
can be reported for distinct ‘early bactericidal’ and ‘ster-
ilizing’ phases of treatment [43,60] and correlation has 
been described between sterilization phase rate co-effi-
cients and long-term DS-TB outcomes [53]. More data 
are required to validate those relationships.
Presently, no early TB outcome measure convincingly 
predicts long-term relapse and there is no consensus on 
which to use. This is demonstrated by the recent failure 
of three multicenter Phase III trials to shorten drug-
susceptible TB treatment from 6 to 4 months by inclu-
sion of a fluoroquinolone [61–63] despite promising results 
from Phase II clinical studies which used end-points of 
2-month SCC [45,64–65], time to culture conversion [65] 
and bacillary elimination rate [59]. Therefore, PK–PD 
studies relating antibiotic exposure to early outcomes 
must be aware of the potential l imitations to their find-
ings. Future clinical PK–PD analyses may be crucial to 
development of better treatment response biomarkers.
Existing clinical PK–PD data
Table 2 describes published studies which have adopted 
a PK–PD approach to relate plasma or serum antibiotic 
exposure to DS-TB treatment efficacy in adults. The 
collective results are difficult to interpret; some studies 
report an association between PK variability and treat-
ment response [66–74] while others do not [75–79]. No 
PK–PD markers consistently emerge as potential pre-
dictors of efficacy in Phase II clinical trials, or targets 
to inform TDM strategies in clinical practice.
There are several potential explanations for these 
mixed results. Pharmacological variability is one of 
many factors influencing TB treatment [34] and may 
have varying impact in different settings. The published 
studies suffer from considerable heterogeneity in design 
and execution. Most reported antibiotic concentrations 
at one or two time-points only, reducing the accuracy of 
C
Max
 and AUC calculations. Only one related PK indices 
to MICs from infecting Mtb isolates [71]. A wide range 
of early and late treatment outcomes measures were 
used. Treatment failure and relapse are relatively rare 
events, so smaller cohorts may have been insufficiently 
powered to demonstrate the effect of antibiotic exposure 
on unfavorable outcome rates. Finally, the majority were 
single-arm observational studies which may have dimin-
ished their ability to detect relationships with treatment 
efficacy; for example, most of the interindividual vari-
ability in rifampicin concentrations in African settings 
was at the lower end of the likely exposure–response 
curve [23–24,73], making it difficult to demonstrate the 
incremental benefit of higher concentrations on steeper 
sections of the curve. Standardization of clinical PK–
PD study design may provide clarification and facilitate 
meta-analysis of data from different sites [81].
So far this review has argued that modern PK–PD 
methods may improve TB treatment but more work 
is required to translate PK–PD data into practically 
useful information for researchers and clinicians. The 
next sections will provide specific examples of ongoing 
work where PK–PD studies are proving beneficial.
Ongoing PK–PD work in DS-TB
DS-TB compromises 95% of TB cases worldwide, 
with a public health approach required to manage large 
numbers of patients in low resource settings. Therefore, 
the main utility of PK–PD work in DS-TB will likely 
be for development of new, dose-optimized, standard 
regimens rather than individual patient TDM.
The clearest example of an antibiotic for which 
dose and exposure–response relationships require re-
analysis is rifampicin, a key sterilizing mycobacterial 
RNA synthesis inhibitor which is critical for achieving 
relapse-free cure with current DS-TB regimens [2].
The current rifampicin dose (10 mg/kg once daily) 
was selected in the 1960s to facilitate 6-month treat-
ment while minimizing expense [82]. Even when costs 
dropped, toxicity concerns discouraged dose e scalation. 
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Table 2. Summary of pharmacokinetic–pharmacodynamic studies to evaluate antibiotic exposure-treatment efficacy 
relationships in adults with drug-susceptible tuberculosis.
Study (year), 
site
n = PK 
sampling
PK 
parameters
MICs Outcome measures Results Ref.
Narita 
(2001), USA
69 RH 
2, 6 h
CMax No Late: TB recurrence 
(presumed relapse) after 
completion of therapy
No effect of R or H PK on t 
outcome
[76]
Weiner 
(2003), USA
133 Rp, H 
1, 2, 5, 24 h
CMax 
AUC0-12 h
No Late: Composite outcome 
of treatment failure and 
relapse
Lower Rp and H AUC0-12h 
associated with poor outcome
[67]
Weiner 
(2003), USA
102 Rp, H 
1, 2, 3, 6, 
24h
CMax 
AUC0-12h 
AUC0-24h
No Late: Composite outcome 
of treatment failure and 
relapse 
Development of rifamycin 
resistance
Lower Rb AUC0-24h associated 
with poor outcome and 
development of antimicrobial 
resistance 
Lower H AUC0-12h associated 
with poor outcome and 
development of rifamycin 
resistance
[66]
Ribera 
(2007), 
Spain
22 RH 
0.5, 1.5, 2, 
3, 4, 6, 8, 
12h
CMax 
AUC0-24h
No Late: Composite outcome 
of treatment failure and 
relapse
No effect of R or H PK on 
outcome
[79]
Chang 
(2008), 
Hong Kong
72 R only 
2, 4h
Cmax No Early: 2-month SCC No effect of R PK on 2-month 
SCC
[75]
Chideya 
(2009), 
Botswana
225 RHZE 
1, 2, 6 h
CMax 
AUC0-6 h
No Late: Composite outcome 
of treatment failure or 
death during therapy
Low CMax for Z (<35 mg/l) 
associated with poor outcome
[68]
Burhan 
(2013), 
Indonesia
167 RHZE 
2hr†
C2 h No Early: 2-month SCC 
Additional post-hoc of ≥ 1 
positive sputum culture at 
4, 8 or 24 weeks
No effect of R, H or E PK on 
2-month SCC 
Low C2h for Z (<35 mg/l) 
associated with ≥ 1 positive 
sputum culture at 4, 8 or 24 
weeks
[69]
Pasipanodya 
(2013), 
South Africa
142 RHZ 
0.5, 1, 1.5, 
2, 2.5, 3, 4, 
6, 8h
CMax 
AUC0-24h
No Early: 2-month SCC 
Late: Composite outcome 
of treatment failure, death 
and relapse
Low CMax for Z (<58.3 mg/l) 
most strongly associated with 
reduced 2-month SCC 
Low AUC0-24h for R (<13 mg.h/l), 
H (<52 mg.h/l) and Z (<363 
mg.h/l) associated with poor 
long-term outcomes
[70]
Chigutsa 
(2014), 
South Africa
154 RHZE 
4-8 samples 
over 7 h
CMax 
AUC0-24h
Yes Early: 8-week sputum 
bacterial elimination rates‡
Low CMax for R (<8.2 mg/l) 
and low AUC0-24h/MIC (<11.3 
mg.h/l) associated with slower 
bacterial elimination
[71]
Prahl (2014), 
Denmark
32 RHZE 
2h
C2h No Late: Treatment failure Treatment failure more 
common with low C2h of both 
R (<8 mg/l) and H (<3 mg/l)
[72]
Requena-
Méndez 
(2014), Peru
113 H 
2, 6h
C2h No Late: Composite outcome 
of treatment failure and 
relapse
No effect of H PK on outcome [78]
†Full PK profile done on a subset of nine patients.
‡Bacterial elimination rates based on time to event modeling from liquid culture data [80].
§Bacterial elimination rates based on mixed effects modeling from solid and liquid culture data [53].
E: Ethambutol; H: Isoniazid; R: Rifampicin; Rb: Rifabutin; Rp: Rifapentine; SCC: Sputum culture conversion; Z: Pyrazinamide. Other abbreviations are as described in 
the main text.
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However, preclinical experiments now suggest that 
increased rifampicin doses (up to 160 mg/kg/day) may 
be tolerable and could shorten treatment [16,83]. Mono-
therapy studies in humans have demonstrated a steeper 
fall in bacterial load over 2–14 days with modest dose 
increases [48,84], and a systematic review of trials includ-
ing rifampicin doses up to 20 mg/kg showed an asso-
ciation between higher doses and faster SCC [82]. In 
2015, a maximum tolerated dose study from Cape Town 
reported rifampicin dosing up to 35 mg/kg without any 
limiting toxicity so further work, beginning at 50 mg/
kg is planned [85]. Data from Bolivia, Nepal and Uganda 
corroborate the absence of rifampicin toxicity to 20 mg/
kg [86]. The accumulative evidence illustrates a need for 
new clinical PK–PD studies of high dose rifampicin use.
Intensive PK sampling and analysis from the Cape 
Town study showed that increased rifampicin doses 
caused ‘super-proportional’ increases in plasma antibi-
otic exposure; doubling the dose from 10 to 20 mg/kg 
was associated with a more than fourfold increase in 
AUC
0–24h
, the average AUC
0–24h
 at 35 mg/kg was almost 
10-fold higher than with standard dosing and the lowest 
recorded AUC
0–24h
 and C
Max
 increased with almost every 
dose step [85]. Although not powered to detect differences 
in microbiological efficacy, there was a trend toward 
faster day 14 sputum bacterial clearance rates on solid 
and liquid media at 35 mg/kg than at lower doses and 
the AUC
0–24h
 of rifampicin at day 14 was a better predic-
tor of 14-day bactericidal activity than the dose admin-
istered (either in ‘mg’ or weight-adjusted as ‘mg/kg’) [85].
A further Multi Arm Multi Stage randomized 
Phase II trial of several novel treatments for DS-TB 
(including high-dose rifampicin, moxifloxacin and 
the experimental compound SQ109) in South Africa 
and Tanzania has since shown reduced time to spu-
tum culture conversion on liquid media at rifampicin 
35 mg/kg across a period of 12 weeks. A 20-patient PK 
sub-study from that cohort confirmed that rifampicin 
dose escalation has a ‘super-proportional’ plasma drug 
exposure effect [87]. Additional PK–PD insights may 
be gleaned from that dataset, and two more Phase II 
trials on the efficacy of high dose rifampicin are yet to 
report (www.clinicaltrials.gov NCT01408914 in Peru 
and NCT00760149 in Tanzania).
While these data are encouraging, caution is 
required. Most high dose rifampicin studies excluded 
HIV co-infected patients or selectively recruited anti-
retroviral therapy naive individuals with high CD4 
counts. Severely immunocompromised HIV patients 
may be at higher risk of poor drug absorption or 
adverse events and, as rifampicin is a potent inducer 
of cytochrome P450 enzymes, higher doses may pres-
ent an increased challenge in the management of 
drug–drug interactions. Future clinical PK–PD stud-
ies should investigate exposure–response on TB out-
comes in this vulnerable population [4]. Furthermore, 
the notorious unreliability of early PD markers at pre-
dicting relapse precludes confidence that rifampicin 
dose escalation will permit treatment shortening until 
completion of definitive trials. One Phase III study, 
Study (year), 
site
n = PK 
sampling
PK 
parameters
MICs Outcome measures Results Ref.
Sloan (2014), 
Malawi
133 RHZE 
2, 6h
CMax 
AUC0-6h
No Early: 2-month SCC 
Early: 8-week sputum 
bacterial elimination rates§ 
Late: Composite outcome 
of treatment failure and 
relapse
Lower AUC0-6h for H and Z 
associated with reduced 
2-month SCC 
Low AUC0-6h for H (<15 mg.h/l) 
associated with slower 
bacillary elimination 
Lower AUC0-6h for H associated 
with poor long term outcomes
[73]
Mah (2015), 
Canada
134 RH 
1-2, 6h
CMax No Early: 2-month SCC Low CMax of H (<3 mg/l) 
associated with reduced 
2-month SCC
[74]
Park (2015), 
South Korea
413 RHZE 
2h
C2h No Early: 2-month SCC 
Late: Composite outcome 
of treatment failure and 
relapse
No effect of R, H or E PK on 
2-month SCC or late outcome
[77]
†Full PK profile done on a subset of nine patients.
‡Bacterial elimination rates based on time to event modeling from liquid culture data [80].
§Bacterial elimination rates based on mixed effects modeling from solid and liquid culture data [53].
E: Ethambutol; H: Isoniazid; R: Rifampicin; Rb: Rifabutin; Rp: Rifapentine; SCC: Sputum culture conversion; Z: Pyrazinamide. Other abbreviations are as described in 
the main text.
Table 2. Summary of pharmacokinetic–pharmacodynamic studies to evaluate antibiotic exposure-treatment efficacy 
relationships in adults with drug-susceptible TB (cont.).
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(RIFASHORT, NCT02581527) will start recruiting 
soon with experimental regimens containing 1200 and 
1800 mg of rifampicin (20–30 mg/kg for 60 kg adults). 
While these data will be valuable it remains to be seen 
whether this level of dose escalation is enough, particu-
larly as current PK–PD and toxicity data s uggest scope 
to go higher.
PK–PD and dose escalation studies have been 
undertaken on other rifamycins. Rifapentine produces 
higher serum concentrations than rifampicin after 
10 mg/kg oral dosing and has a longer half-life (15 h, 
compared with 2–3 h for rifampicin) [34]. Dose increases 
to 20 mg/kg have been tolerated by healthy volunteers, 
although the rises in plasma AUC
0–24h
 associated with 
higher doses were not super-proportional [88]. C linical 
trials including rifapentine are ongoing (TBTC Study 
31, NCT02410772). Rifabutin is sometimes substituted 
for rifampicin in patients with high drug–drug interac-
tion risks because it is less potent inducer of cytochrome 
P450 enzymes [89]. Its absorption is variable in HIV 
patients [90] and toxicities (including leucopenia and 
uveitis) are concentration dependent. TDM is highly 
recommended and dose increases may be problematic.
Alongside the rifamycins, administration of pyrazin-
amide for the first 2 months of treatment is key to the 
sterilizing efficacy of 6-month first-line regimens for 
DS-TB [2]. Pyrazinamide primarily exerts antitubercu-
lous activity in acidic conditions. While early bacteri-
cidal activity studies with pyrazinamide demonstrated 
poor independent bactericidal activity over 14 days, it 
enhanced the activity of other drugs [48] and some clini-
cal PK–PD studies have shown that reduced exposure 
is associated with poor late outcomes [68–70]. The popu-
lation PK profile of pyrazinamide is more stable than 
rifampicin or isoniazid so predictable plasma concentra-
tions are usually achieved [20,24]. The currently recom-
mended dose is 20–30 mg/kg. Concerns about side-
effects of arthralgia and dangerous hepatotoxicity have 
stifled calls for dose escalation. However, preclinical 
data suggest that doses up to 60 mg/kg could improve 
efficacy [13]. A meta-analysis of dose-toxicity relation-
ships in clinical studies reported that, although arthral-
gia is dose-related, higher dose pyrazinamide did not sig-
nificantly increase hepatotoxicity and some adverse liver 
events may be idiosyncratic [91]. Computer simulations 
suggest that modest pyrazinamide dose increases (up to 
40 mg/kg) alongside higher dose rifampicin may accel-
erate 2-month SCC. Clinical trials with nested PK–PD 
analyses and toxicity monitoring are planned to test this 
proposition.
Pharmacological lessons on optimal dosing and 
drug–drug interactions may yet emerge from the 
Phase III fluoroquinolone trials which failed to shorten 
DS-TB therapy [61–63]. A PK sub-study of the OFLO-
TUB trial [61] identified that gatifloxacin exposure 
decreased with rifampicin, isoniazid and pyrazinamide 
co-administration; and that double-dose gatifloxacin 
may optimize the bactericidal effect and reduce the 
probability of resistance [92]. Similarly, drug–drug 
interactions between rifampicin and isoniazid and 
moxifloxacin reduce moxifloxacin C
max
 and AUC by 
32 and 31%, respectively [93]. Refinement of fluoroqui-
nolone dosing through PK–PD studies may improve 
outcomes in future trials.
Ongoing PK–PD work in MDR-TB
Treatment of MDR-TB is more difficult than DS-TB, 
with lower treatment success rates and higher in cidence 
of treatment limiting toxicity [9]. Traditional and 
emerging regimens combine new compounds with old 
second-line drugs [8] (see Figure 2) and the evidence to 
support optimal dose combinations is sparse. There is, 
therefore, considerable scope for clinical PK–PD stud-
ies to support optimization of standard drug dosing 
and TDM. Due to space constraints, two illustrative 
examples are provided here.
The oxazolidinone, linezolid, has recently been re-
classified as a ‘core second line agent’ for MDR-TB 
treatment [8] (see Figure 2) and may be particularly 
important for patients with extensive antimicrobial 
resistance [94–96]. Prolonged therapy is complicated 
by serious side-effects; bone marrow suppression and 
peripheral or optic neuropathy are reported in 28% 
of patients [8]. The routine dose (600 mg orally, twice 
daily), licensed for treatment of Gram positive non-
mycobacterial infections, is currently being formally 
evaluated alongside bedaquiline and pretomanid in the 
Nix-TB trial (NCT02333799). To increase tolerability 
doses of 600 mg daily, 300 mg twice daily and 300 mg 
once daily are often administered under programmatic 
conditions [97] and a 600 mg daily dose will be assessed 
as part of several five drug regimens in the NEXT-TB 
trial (NCT02454205). A systematic review has ten-
tatively indicated that 300 mg twice daily daily may 
retain efficacy while avoiding toxicity but there were 
difficulties in selecting end points for this retrospective 
PK–PD analyses [98]. Prospectively collected data are 
required and recruitment is ongoing to a dose ranging 
study in South Africa.
Although it is hoped that all-oral treatment for 
MDR-TB will be available in the future, amino-
glycosides (amikacin and kanamycin) are currently 
integral to all approved regimens. Longer duration, 
higher doses of these drugs (WHO recommended 
range: 15–20 mg/kg/day up to a maximum of 1000 
mg daily [8]) contributes to favorable outcomes [99] 
but the therapeutic index is narrow; nephrotoxicity 
and irreversible ototoxicity are common [100]. TDM is 
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Figure 2.  WHO-approved MDR-TB treatment regimens. 
*Streptomycin may substitute for other injectable agents in specific scenarios. 
‡Thioacetazone must not be used in HIV co-infection. 
§This template should be adapted to the antimicrobial resistance profile of the infecting Mtb isolate. If a regimen 
containing 5 drugs which are likely to be effective cannot be constructed additional group D1-3 agents should be 
added. 
¶Most patients will require a second-line injectable agent for 8 months and total treatment for 20 months but 
there is scope for modification according to patient response. 
#The 9-12 regimen may only be used when resistance to fluoroquinolones and second-line injectable agents has 
been excluded or is considered unlikely.  
**Patients who do not adequately respond to therapy (e.g., sputum smear conversion by 4 months) may have the 
intensive phase of therapy extended. 
Group A Levooxacin
Moxioxacin
Gatioxacin
(Fluoroquinolones)
Group B
(second-line
injectable agents)
Amikacin
Capreomycin
Kanamycin
(Streptomycin)*
Group C
(other core
second-line
agents)
Ethionamide/prothionamide
Cycloserine/terizidone
Linezolid
Clofazimine
Group D1
(rst-line drugs)
Pyrazinamide
Ethambutol
High-dose isoniazid
Group D2
(new agents)
Bedaquiline
Delamanid
Group D3
(non-core second
line agents)
P-aminosalicylic acid
Imipenem-cilastatin
Meropenem
Amoxicillin-clavulanate
(thioacetazone)‡ 
Standard MDR-TB treatment§,¶ 
8 months
1 Group A drug
1 Group B drug
≥ 2 Group C drugs
Pyrazinamide (D1)
12 months
1 Group A drug
2 Group C drugs
Pyrazinamide (D1)
Recently approved 9–12 MDR-TB regimen#
4 months**
Moxioxacin or gatioxacin (A)
Kanamycin (B)
Priothionamide (C)
Clofazimine (C)
High-dose isoniazid (D1)
Pyrazinamide (D1)
Ethambutol (D1)
5 months
Moxioxacin or gatioxacin (A)
Clofazimine (C)
Pyrazinamide (D1)
Ethambutol (D1)
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tr aditionally recommended to guide aminoglycoside 
therapy by assaying ‘peak’ and ‘trough’ drug concen-
trations. However, recent HFS [101] experiments and 
clinical PK–PD studies in Botswana [102] have sug-
gested C
Max
/MIC and AUC
0–24h
/MIC to be better pre-
dictors of treatment efficacy (the clinical studies were 
based on sputum culture conversion) while cumulative 
AUC
0–24h
/MIC and duration of therapy correlate best 
with the risk of ototoxicity [103]. In the Netherlands, 
individualized aminoglycoside dosing based on C
Max
/
MIC resulted in patients receiving an average dose of 
6.7 mg/kg [30], which is significantly lower than the 
WHO recommendation. A retrospective evaluation 
of the regimen incorporating this approach showed 
f avorable results [104]. Further studies are required but 
this saliently illustrates how suitable PK–PD thresh-
olds might support safer individualized therapy based 
on TDM.
Clinical pharmacologists may also help to address 
further MDR-TB therapeutics issues, including: the 
role of higher fluoroquinolone doses for patients with 
resistance mutations conferring modestly elevated 
MICs [40,105]; the synergistic or antagonistic effects of 
new antituberculous compounds in combination; and 
exposure-toxicity aspects of electrocardiographic QTc 
prolongation by drugs such as fluoroquinolones, clo-
fazimine, bedaquiline and delamanid [106]. There is 
insufficient space for detailed discussion of these. The 
remainder of this review will consider emerging chal-
lenges and opportunities for the design and conduct of 
future PK–PD studies.
New assays & outcome measures
Practical aspects of PK sample collection and process-
ing have already been outlined. An additional consider-
ation is that several antibiotics are metabolized to other 
active compounds after administration (e.g., rifampi-
cin is converted to 25-desacetylrifampicin and pyrazin-
amide is the pro-drug of pyrazinoic acid [107]). Assays 
of all active metabolites may be needed to understand 
the PK–PD characteristics of such agents.
Limitations of sputum culture-based early TB out-
come measures have also been discussed. A molecular 
bacterial load assay has recently been developed which 
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reports the Mtb bacterial load by quantitation of 16S 
ribosomal RNA within 72 h of sample processing [108]. 
This is much faster than the turnaround time for cul-
ture. Changes in the molecular bacterial load assay on 
therapy may allow more efficient TB treatment moni-
toring [109] and help to develop better outcome mea-
sures for TDM and clinical trials. The impact of this 
technique will depend on validation of data against 
long-term relapse.
Interindividual variability & special 
populations
Wide interindividual variability in the plasma expo-
sure of some antituberculous antibiotics partly under-
pins the rationale for clinical PK–PD studies [19–22]. 
Co-morbidities, concomitant medications, dietary 
intake and genetic factors regulating drug metabolism 
all contribute. Greater understanding of the role played 
by genotype may identify patients at high risk of low 
exposure, potentially focusing TDM and earlier inter-
vention to improve outcomes.
Isoniazid clearance is driven by N-acetyltransferase 
2 enzymes in the liver and small intestine, regulated 
by the polymorphic NAT2 gene [110]. Single nucleotide 
polymorphisms in several NAT2 alleles confer fast or 
slow acetylation phenotypes [110,111]. Low isoniazid 
exposure in fast acetylators may be associated with 
increased risk of unfavorable outcomes and acquired 
drug resistance while high exposure in slow acetylators 
may be associated with toxicity [111]. Given the domi-
nant effect of NAT2 genotype on isoniazid exposure, 
practicing clinicians and researchers should consider 
categorizing patients by acetylator status.
Genotypic drivers of rifampicin variability are 
less clear. Biliary excretion occurs after hepatocel-
lular uptake, primarily mediated by organic anion-
transporting polypeptide 1B1 coded for by the gene 
SLCO1B1 [112]. Recent reports from South Africa and 
Uganda suggest that single nucleotide polymorphisms 
in SLCO1B1 are more common in African patients 
and associated with up to 28% reduction in rifampi-
cin AUC
0–24hr
 in homozygotes [112,113]. However, given 
extensive population diversity in SLCO1B1 polymor-
phism carriage [114], these findings have not been repli-
cated in India, Tanzania or Malawi [115,116,117]. Future 
PK–PD studies should investigate further.
Some PK variability is associated with physiologi-
cally distinct, but previously neglected populations 
where a strong case exists for separate PK–PD studies 
and clinical trials. Foremost among these are children. 
Previously, pediatric dosing and duration of first-line 
TB therapy were extrapolated on a mg/kg basis from 
adult studies, but this resulted in lower plasma concen-
trations than the adult population. In 2010, the WHO 
recommended increased doses of all four first-line TB 
drugs [118]. Few PK studies have been performed to 
assess the impact of these adjustments. Emerging data 
from South Africa and Malawi indicate that  rifampicin 
Table 3. Pharmacokinetic sampling sites.
Sampling site Advantages Disadvantages
Peripheral blood (plasma 
or serum)
Ease of repeat sampling 
Multiple/rich PK sampling possible 
Most existing data for comparison are from 
these samples
Far from site of infection 
Unclear relationship with outcome 
Wide interindividual variability
Bronchoalveolar lavage ‘Near infection’ samples - alveolar macrophages 
and epithelial lining fluid 
Can be paired with rich plasma/serum sampling 
Models of intrapulmonary exposure can 
be developed using population modeling 
techniques
Invasive procedure 
Single time point sampling 
Sample from alveoli and bronchioles rather 
than within granuloma 
Drug loss due to efflux when sampling 
Differential penetration depending on 
inflamed/noninflamed lung/different lobes 
Sampling retrieves mixture of macrophages, 
T-lymphocytes and epithelial cells
Lung explant studies Can assess spatial drug penetration 
Can combine with spatial data on drug 
susceptibility profile and MIC
Only possible in patients requiring lung 
resection (either severe disease or a sub-set of 
MDR-TB patients) 
Single time point drug concentrations
Cerebrospinal fluid 
(for TB meningitis)
Accessible 
Can be paired with rich plasma sampling 
Models of CSF drug exposure can be developed 
using population modeling techniques
Invasive procedure 
Single time point sampling 
Traumatic tap will contaminate samples
CSF: Cerebrospinal fluid; MDR: Multidrug resistant; MIC: Minimum inhibitory concentration.
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exposures remain low [119,120]. A cohort evaluation of 
161 Indian children aged 1–15 has suggested that a 
low C
Max
 for rifampicin (<3.01 mg/l) or pyrazinamide 
(<38.01 mg/l) predicted late outcomes of treatment 
failure or death [121]. There is almost no clinical PK–
PD information on second-line drugs for MDR-TB in 
pediatric populations.
Although the evidence is debatable, patients with 
HIV co-infection [23,122] diabetes mellitus [123–125] and 
pregnant women [126] may also have unusual PK–PD 
profiles, necessitating detailed sub-studies to clarify 
the role of TDM and altered antibiotic dosing. Sys-
tematic use of early TDM with dose correction in 
diabetic patients may shorten time to sputum culture 
c onversion [127].
PK–PD at the site of disease
All the PK–PD data described hitherto report antibi-
otic exposure in peripheral blood, but TB is not primar-
ily a bloodstream infection. In pulmonary TB, Mtb 
exists within discrete microenvironments: intracellular 
organisms within granuloma macrophages; free extra-
cellular organisms in caseum, cavities and airways; and 
in apparently ‘normal’ interstitial lung tissue [128]. It is 
improbable that unbound drug passively equilibrates 
between blood and all tissue compartments so inves-
tigation of relationships between peripheral blood and 
lesion PK–PD is important. Advantages and disadvan-
tages of clinically focused methods for this are outlined 
in Table 3.
One novel approach is to generate spatial drug pene-
tration information by performing matrix-assisted laser 
desorption/ionization mass spectrometry on dissected 
tissue from patients undergoing lung resection surgery 
for antibiotic-refractory disease [5,129]. Early results 
suggest excellent rifampicin and pyrazinamide pene-
tration into the central necrotic caseum of TB granulo-
mas but peripheral intracellular accumulation of moxi-
floxacin [130]. These data may explain why rifampicin 
and pyrazinamide are critical DS-TB sterilizing agents 
but treatment shortening trials with moxifloxacin were 
unsuccessful [62,63]. However, an alternative approach 
using microdialysis on ex vivo pulmonary cavities 
from patients with MDR-TB shows excellent penetra-
tion of levofloxacin into cavity walls, and good cor-
relation between serum and cavitary fluoroquinolone 
concentrations [131]. From a PD perspective, lung resec-
tion studies have shown differing drug susceptibility 
patterns in Mtb isolates from different pulmonary 
cavities of the same patient [132,133] and mathematical 
models suggest that bacilli in compartments with low 
antibiotic penetration develop higher MICs. Overall, 
such advanced PK–PD work on resected lung tissue 
is beginning to generate very detailed information on 
the extent and consequences of antibiotic exposure at 
the site of infection. A disadvantage of these experi-
ments is that they are only possible on a small sub-set 
of unusual and highly selected patients with very severe 
TB and particularly distorted lung anatomy.
An alternative means of ‘near infection’ PK sam-
pling is the use of broncho-alveolar (BAL) lavage 
to sample epithelial lining fluid (ELF) and alveolar 
macrophages. Given the invasive nature of this pro-
cedure, all previous BAL studies were conducted on 
small numbers of healthy volunteers with single time-
point sampling. Results show extensive variability in 
the pulmonary penetration of first-line drugs. In ELF, 
isoniazid concentrations appeared low in relation to 
likely MICs for clinical Mtb isolates and projected 
rifampicin AUC/MIC measurements appeared insuf-
ficient to suppress resistance in a high proportion of 
subjects [134–138]. Alveolar macrophage/ELF concen-
tration ratios ranged from 0.1 to >20, with rifampi-
cin, ethambutol and fluoroquinolones concentrating 
most effectively within cells [5,136,139]. Difficulties for 
BAL-based studies are the potential clinical hazard 
and infection control risks associated with perform-
ing bronchoscopies on sick patients and the need to 
collect luminal specimens rather than those directly 
from granulomas. An ongoing clinical PK–PD cohort 
of TB patients with BAL sampling in Malawi will 
provide new information.
Fifteen to twenty percent of TB cases are extra-pul-
monary. Penetration of antibiotics to other infection 
sites may differ from the lungs. Specific PK–PD studies 
have been completed in TB meningitis, where treat-
ment regimens derived from data on pulmonary TB do 
not account for the extent of drug penetration across 
the blood–brain barrier. Isoniazid, pyrazinamide and 
the fluoroquinolones reach cerebrospinal fluid (CSF) 
in high concentrations, whereas streptomycin does 
not [140]. Interestingly, for fluoroquinolones both ‘low’ 
and ‘high’ CSF drug exposures are associated with 
poorer outcomes, and intermediate exposures are asso-
ciated with less death and disability [141]. It is likely that 
more extensive breakdown of the blood–brain barrier 
with severe disease explains the link between higher 
drug exposure and poorer outcomes.
CSF rifampicin exposure is lower than plasma [142]. 
A Phase II clinical trial of rifampicin (13 mg/kg) intra-
venously alongside moxifloxacin, isoniazid, pyrazin-
amide and corticosteroids in Indonesia identified a 
survival benefit from higher CSF rifampicin concen-
trations, with substantially lower 6-month mortality 
in patients receiving the higher dose [143,144]. Con-
versely, a Phase II trial in Vietnam, using oral rifam-
picin (15 mg/kg) and levofloxacin (20 mg/kg) did 
not improve survival [145]. More studies are needed to 
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determine whether rifampicin dose escalation, perhaps 
allied to intravenous administration, does improve 
o utcomes [85,146].
Conclusion
Current treatment regimens for DS-TB and MDR-TB 
are not based on a detailed understanding of exposure–
response relationships for the antibiotic combinations 
which are used. Development of shorter, less toxic 
therapeutic strategies for all forms of TB is a key global 
research priority. Preclinical studies in animals and 
HFS have indicated that clinical PK–PD studies may 
contribute toward achievement of this goal by helping 
to optimize dosing for new standard regimens and, in 
some cases, by providing an evidence base for TDM to 
guide the management of individual patients.
Future perspective
After many barren years in TB drug development, 
intensified efforts to accelerate the evaluation combi-
nations of existing antibiotics alongside novel com-
pounds are beginning to bear fruit and there are real 
opportunities to improve treatment outcomes. PK–PD 
science will make an important contribution to this 
endeavor, increasing the chance of success, especially 
if insights from preclinical HFS work can be validated 
and extended by clinical PK–PD studies.
The greatest impact may be obtained at the level of 
Phase II clinical trials. If analysis of PK–PD param-
eters in relation to early treatment outcomes (mea-
sured ∼8 weeks into treatment for DS-TB) could 
predict the long-term risk of eventual relapse, more 
efficacious regimens might advance more quickly to 
Phase III evaluation. This would accelerate progress 
toward shorter therapy with attendant benefits for 
all patients. However, early treatment outcomes are 
currently poor surrogates of final end points and it 
remains to be seen whether new monitoring tools 
will help overcome this obstacle. Standardization of 
PK–PD study design and meta-analyses of larger total 
datasets may pave the way forward [81].
TDM may be of value in patients from groups 
with unpredictable PK characteristics (e.g., in the 
presence of HIV infection, potential drug–drug 
interactions or renal/hepatic dysfunction). It may 
also improve the treatment of MDR-TB where sev-
eral drugs have a narrow therapeutic index. For this 
approach to be effectively exploited, plasma con-
centration ranges associated with safe and success-
ful TB treatment need to be better defined. That 
is currently problematic, given the scarcity of PK–
PD datasets for second-line antituberculous drugs 
but this knowledge gap provides fertile ground for 
future research. A large prospective cohort enrolling 
in Bangladesh, Tanzania, Uganda and Siberia may 
help to address this knowledge gap for some special 
population groups (NIH U01 ICIDR AI119954) 
but additional studies are needed.
Emerging and overdue priority areas for TB phar-
macologists are specific design of antibiotic regimens 
Executive summary
Background & rationale for clinical pharmacokinetic-pharmacodynamic studies of TB treatment
•	 Shorter, less toxic treatment regimens are urgently required for all forms of TB.
•	 Clinical pharmacokinetic-pharmacodynamic (PK–PD) studies may help improve the conduct of Phase II clinical trials, and facilitate 
therapeutic drug monitoring for some drugs.
Existing studies & their limitations
•	 Results are variable but some show associations between low plasma CMax or AUC measurement for first-line drugs and treatment 
response.
•	 Inconsistency in study design and selection of outcome measures contributes to difficulty in collective interpretation of prior data.
Ongoing PK–PD work in drug-susceptible TB
•	 Increased rifampicin doses for patients with pulmonary DS-TB may be associated with super-proportional increases in the AUC0–24h 
and faster sputum sterilization.
•	 PK–PD modeling suggests that higher dose pyrazinamide may be possible.
•	 Fluoroquinolones doses may require to be increased to account for the effect of drug–drug interactions.
Ongoing PK–PD work in multidrug resistant TB
•	 The optimal dose of linezolid, to maximize efficacy while minimizing toxicity, is under evaluation.
•	 Therapeutic drug monitoring for aminoglycosides may be better targeted against CMax/MIC and AUC0–24h/MIC than traditional 
‘peak’ and ‘trough’ measurements.
•	 Many additional questions require attention, including the efficacy and toxicity of novel drug combinations (e.g., bedaquiline and 
delamanid).
Challenges for future studies
•	 PK–PD study design should consider incorporating assays of active drug metabolites and free drug fractions. New treatment 
monitoring tools should be considered when selecting early outcome measures.
•	 PK–PD studies and clinical trials should be specifically designed for children and other special populations.
•	 PK–PD analyses at the site of infection may provide additional insights into the factors driving treatment efficacy.
207www.future-science.comfuture science group
Importance of clinical PK–PD studies in unraveling the determinants of early & late TB outcomes   Review
for children and patients with extra-pulmonary TB. 
Frameworks are being developed for pediatric-focused 
HFS-based PK–PD studies [147] and it is to be hoped 
that clinical studies will follow.
Overall, despite numerous unanswered questions 
and technical challenges, the landscape has rarely 
been more optimistic in TB therapeutics. Judicious 
evaluation of novel antibiotic combinations carries 
real potential for better, safer and shorter treatment 
for all patient groups. Clinical PK–PD studies have an 
important role to play in achieving that goal.
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